

# Christof Specker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8380111/publications.pdf>

Version: 2024-02-01

78  
papers

3,877  
citations

101543

36  
h-index

144013

57  
g-index

134  
all docs

134  
docs citations

134  
times ranked

4324  
citing authors

#	ARTICLE	IF	CITATIONS
1	High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. <i>Lupus</i> , 1998, 7, 113-118.	1.6	194
2	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011, 13, R75.	3.5	170
3	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
4	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	1.0	133
5	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	2.4	118
6	Jaccoud's arthropathy in systemic lupus erythematosus: Differentiation of deforming and erosive patterns by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003, 48, 157-165.	6.7	113
7	Glucocorticoid receptors in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1992, 35, 740-744.	6.7	101
8	Self-assessments of patients via Tablet PC in routine patient care: comparison with standardised paper questionnaires. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1739-1741.	0.9	90
9	Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2021, 7, e001464.	3.8	82
10	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 267-276.	13.7	78
11	Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. <i>Rheumatology</i> , 2013, 52, 1070-1076.	1.9	77
12	Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID). <i>Lupus</i> , 2013, 22, 1142-1149.	1.6	74
13	Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 397-414.	3.3	74
14	Current state of evidence on “off-label” therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report. <i>Lupus</i> , 2012, 21, 386-401.	1.6	71
15	The German National Registry of Primary Immunodeficiencies (2012–2017). <i>Frontiers in Immunology</i> , 2019, 10, 1272.	4.8	71
16	Mutations in the prostaglandin transporter encoding gene <i>SLCO2A1</i> Cause primary hypertrophic osteoarthropathy and isolated digital clubbing. <i>Human Mutation</i> , 2012, 33, 660-664.	2.5	69
17	Acquired factor VIII inhibitors in nonhemophilic patients. <i>Annals of Hematology</i> , 1997, 74, 89-93.	1.8	68
18	First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. <i>Rheumatology and Therapy</i> , 2016, 3, 271-290.	2.3	60

#	ARTICLE	IF	CITATIONS
19	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	6.5	60
20	Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 600-603.	1.2	56
21	Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1090-1097.	0.9	56
22	Rituximab as a Treatment Option for Refractory Endogenous Anterior Uveitis. <i>Ophthalmic Research</i> , 2007, 39, 184-186.	1.9	54
23	Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R150.	3.5	54
24	Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2012, 51, 1188-1197.	1.9	52
25	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.9	49
26	Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. <i>Lupus</i> , 2012, 21, 1183-1189.	1.6	48
27	Cerebral microemboli in patients with antiphospholipid syndrome. <i>Lupus</i> , 1997, 6, 638-644.	1.6	44
28	CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , 2006, 145, 235-242.	2.6	44
29	National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. <i>RMD Open</i> , 2020, 6, e001332.	3.8	44
30	Cerebral Microembolism in Patients With Sneddon's Syndrome. <i>Archives of Neurology</i> , 1995, 52, 271-275.	4.5	43
31	CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 161-171.	0.7	43
32	Molecular imaging of cartilage damage of finger joints in early rheumatoid arthritis with delayed gadolinium-enhanced magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2012, 64, 394-399.	6.7	42
33	Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 840-842.	0.9	38
34	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. <i>Journal of Rheumatology</i> , 2019, 46, 279-284.	2.0	36
35	Antiphospholipid syndrome in cardiac surgery – an underestimated coagulation disorder? <i>European Journal of Cardio-thoracic Surgery</i> , 2005, 28, 133-137.	1.4	34
36	Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. <i>Deutsches Arzteblatt International</i> , 2017, 114, 197-203.	0.9	34

#	ARTICLE	IF	CITATIONS
37	Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. <i>Rheumatology International</i> , 1995, 15, 23-29.	3.0	33
38	German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. <i>Rheumatology International</i> , 2014, 34, 1-9.	3.0	33
39	Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?. <i>Acta Neurologica Scandinavica</i> , 1999, 99, 356-361.	2.1	32
40	Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID). <i>Journal of Rheumatology</i> , 2012, 39, 2153-2156.	2.0	32
41	Increased percentages of PD-1 on CD4 <sup>+</sup> T cells is associated with higher INF- $\gamma$ production and altered IL-17 production in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 307-313.	1.1	31
42	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.8	30
43	Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the national database of the German Collaborative Arthritis Centres. <i>Lupus</i> , 2004, 13, 529-536.	1.6	28
44	Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 1-9.	1.0	28
45	Relapsing polychondritis in childhood - case report and short review. <i>Rheumatology International</i> , 2000, 19, 231-234.	3.0	27
46	Hereditary Periodic Fever With Systemic Amyloidosis: Is Hyper-IgD Syndrome Really a Benign Disease?. <i>American Journal of Kidney Diseases</i> , 2006, 48, e41-e45.	1.9	27
47	Peripheral Circulating Activated B-cell Populations are Associated with Nephritis and Disease Activity in Patients with Systemic Lupus Erythematosus. <i>Scandinavian Journal of Immunology</i> , 2007, 66, 584-590.	2.7	26
48	BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4505.	4.1	24
49	Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines. <i>RMD Open</i> , 2021, 7, e001553.	3.8	23
50	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, e001896.	3.8	22
51	Utility of combined high-resolution bone SPECT and MRI for the identification of rheumatoid arthritis patients with high-risk for erosive progression. <i>European Journal of Radiology</i> , 2013, 82, 374-379.	2.6	18
52	Antiphospholipid Antibodies in Systemic Lupus Erythematosus and Sneddon's Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 1994, 20, 55-63.	2.7	16
53	Detection of cerebral microemboli in APS "Introducing a novel investigation method and implications of analogies with carotid artery disease. <i>Lupus</i> , 1998, 7, 75-80.	1.6	16
54	Synovitis and bone inflammation in early rheumatoid arthritis: high-resolution multi-pinhole single-photon-emission computed tomography (mph-spect) versus magnetic resonance imaging (mri). <i>Diagnostic and Interventional Radiology</i> , 2012, 19, 20-4.	1.5	16

#	ARTICLE	IF	CITATIONS
55	Antiphospholipid syndrome complicating chronic graft-versus-host disease after allogeneic bone marrow transplantation. <i>American Journal of Hematology</i> , 1994, 47, 143-144.	4.1	15
56	An askâ€œtheâ€œexpert service on a rheumatology web site: Who were the users and what did they look for?. <i>Arthritis Care and Research</i> , 2011, 63, 604-611.	3.4	14
57	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 33-48.	1.0	13
58	RheumaNet--a novel Internet-based rheumatology information network in Germany. <i>Rheumatology</i> , 1998, 37, 1015-1019.	1.9	12
59	Hypogonadism in Wegener's granulomatosis. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 365-369.	1.1	11
60	The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany. <i>Rheumatology</i> , 2021, 60, S151-S158.	1.9	11
61	Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus. <i>Rheumatology International</i> , 2003, 23, 319-323.	3.0	10
62	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2â€œmethodology, key messages and justifying information. <i>Rheumatology</i> , 2021, 60, 2128-2133.	1.9	10
63	Arthroscopic synovectomy and radiosynoviorthesis: a treatment option for recurrent arthritis symptoms in patients with pachydermoperiostosis. <i>Reumatismo</i> , 2013, 65, 82-5.	0.9	8
64	HLA class II genes and antibodies against recombinant U1-nRNP proteins in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 1994, 14, 63-69.	3.0	7
65	IL-22 production of effector CD4+ T-cells is altered in SLE patients. <i>European Journal of Medical Research</i> , 2019, 24, 24.	2.2	6
66	Response to: â€œTreatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemicâ€œ™ by Fragoulis et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e61-e61.	0.9	6
67	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, .	3.8	6
68	Immunoglobulin allotypes in systemic lupus erythematosus--results of a central European multicenter study. SLE Study Group. <i>Experimental and Clinical Immunogenetics</i> , 1991, 8, 11-5.	1.2	5
69	Immunoglobulin allotypes are not associated with HLA-antigens, autoantibodies and clinical symptoms in systemic lupus erythematosus. <i>Rheumatology International</i> , 1991, 11, 179-182.	3.0	4
70	A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany. <i>Rheumatology International</i> , 2021, 41, 1949-1956.	3.0	4
71	Swimming against the stream: the fishbowl discussion method as an interactive tool for medical conferences: experiences from the 11th European Lupus Meeting. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 713-714.	0.9	3
72	Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e.â€œV.). <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 10-12.	1.0	2

#	ARTICLE	IF	CITATIONS
73	OP0099â€¦Safety, tolerability and initial signs of efficacy of the fully human immunocytokine DEKAVIL (F8IL10): a novel therapeutic approach for rheumatoid arthritis. , 2017, , .		1
74	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 319-328.	0.8	1
75	OP0074â€¦Platelet cd40 l expression in sle and antiphospholipid syndrome. , 2001, , .		0
76	FRI0178â€¦Followup of platelet activation in a patient with antiphospholipid syndrome upon tirofiban treatment. , 2001, , .		0
77	Rheumatologie. , 2017, , 469-497.		0
78	The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. Clinical and Experimental Rheumatology, 2021, , .	0.8	0